Literature DB >> 26849064

Treatment adherence in newly diagnosed type 2 diabetes: patient characteristics and long-term impact of adherence on inpatient care utilization.

Peter Sun1, Jean Lian2.   

Abstract

OBJECTIVES: The purpose of this study was to evaluate the impact of antidiabetic medication adherence on hospital utilization in patients with newly diagnosed type 2 diabetes mellitus (T2D). This study specifically analyzed patients with newly diagnosed T2D with the intent of lessening intragroup disease severity differences, and adjusting for a range of other clinical and demographic characteristics.
METHODS: This retrospective US claims database study evaluated adults with newly diagnosed T2D who started antidiabetic medications in 2005-2009, had ≥ 2 antidiabetic medication claims after their first (baseline). Medication adherence was evaluated using the medication possession ratio (MPR) of any or all antidiabetic medication(s) during the 3-year post-baseline period. Repeated-measures analyses examined changes in inpatient utilization from the pre- to post-baseline period. The impact of adherence on hospital utilization during the post-baseline period was evaluated with a logistic regression model to adjust for confounding factors.
RESULTS: The study included 192,717 patients (mean age, 55.0 years). Mean MPR for antidiabetic therapy was 0.74. MPR was highest in elderly patients and Medicare beneficiaries. Mean annualized inpatient admissions during the 3-year post-baseline period were significantly lower in patients with MPR ≥ 0.80 (1.4) than in those with MPR < 0.80 (2.2; P < 0.05). Logistic regression analysis, adjusting for patient characteristics and prior inpatient utilization, showed 39% lower odds of hospitalization (OR = 0.61; 95% CI = 0.534-0.693) for patients with MPR ≥ 0.80. People with T2D-related complications or hospitalization had approximately 2- to 3-fold higher risk of subsequent hospitalization.
CONCLUSIONS: In newly diagnosed T2D patients with antidiabetic therapy in the first three ensuing years, higher antidiabetic medication adherence was significantly associated with lower hospital inpatient utilization before and after adjusting for patient characteristics.

Entities:  

Keywords:  Medication adherence; drug therapy; inpatient care; medication possession ratio; newly diagnosed; payer type; retrospective cohort study; type 2 diabetes mellitus; utilization

Mesh:

Year:  2016        PMID: 26849064     DOI: 10.1080/00325481.2016.1151326

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  4 in total

1.  2016 Writing Contest Undergraduate Winner: The Relationship Between Medication Adherence and Total Healthcare Expenditures by Race/Ethnicity in Patients with Diabetes in Hawai'i.

Authors:  Cori X Sutton; Dee-Ann Carpenter; Wesley Sumida; Deborah Taira
Journal:  Hawaii J Med Public Health       Date:  2017-07

Review 2.  Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review.

Authors:  Marc Evans; Susanne Engberg; Mads Faurby; João Diogo Da Rocha Fernandes; Pollyanna Hudson; William Polonsky
Journal:  Diabetes Obes Metab       Date:  2021-12-09       Impact factor: 6.408

3.  Associations of different adherences in patients with type 2 diabetes mellitus.

Authors:  Andrea Klinovszky; István Márton Kiss; Orsolya Papp-Zipernovszky; Csaba Lengyel; Norbert Buzás
Journal:  Patient Prefer Adherence       Date:  2019-03-15       Impact factor: 2.711

4.  Association between nutritional guidance or ophthalmological examination and discontinuation of physician visits in patients with newly diagnosed diabetes: A retrospective cohort study using a nationwide database.

Authors:  Akira Okada; Sachiko Ono; Satoko Yamaguchi; Hayato Yamana; Kayo Ikeda Kurakawa; Nobuaki Michihata; Hiroki Matsui; Masaomi Nangaku; Toshimasa Yamauchi; Hideo Yasunaga; Takashi Kadowaki
Journal:  J Diabetes Investig       Date:  2021-02-28       Impact factor: 4.232

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.